Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment

被引:8
|
作者
Lobetti-Bodoni, Chiara [1 ]
Ferrero, Dario [1 ]
Genuardi, Elisa [1 ]
Passera, Roberto
Bernocco, Elisa [1 ]
Sia, Daniela [2 ]
Grignani, Giovanni [3 ]
Crisa, Elena [1 ]
Monitillo, Luigia [1 ]
Rocci, Alberto [1 ]
Drandi, Daniela [1 ]
Giai, Valentina [1 ]
Zanni, Manuela [1 ]
Boi, Michela [1 ]
Isaia, Gianluca [4 ]
Barbero, Daniela [1 ]
Lunghi, Monia [5 ]
Abruzzese, Elisabetta [6 ]
Radaelli, Franca [7 ]
Pini, Massimo [8 ]
Pregno, Patrizia [9 ]
Carlo-Stella, Carmelo [2 ]
Gaidano, Gianluca [5 ]
Boccadoro, Mario [1 ]
Ladetto, Marco [1 ]
机构
[1] Univ Turin, Div Hematol, AOU San Giovanni Battista, Turin, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Inst Canc Res & Treatment IRCC, Med Oncol Unit, Candiolo, Italy
[4] Univ Turin, Dept Med & Surg, Geriatr Sect, Turin, Italy
[5] Amedeo Avogadro Univ Eastern Piedmont, Dept Clin & Expt Med, Div Hematol, Novara, Italy
[6] Tor Vergata Univ Hosp, Dept Hematol, Rome, Italy
[7] Fdn IRCCS Policlin, Milan, Italy
[8] AO SS Antonio & Biagio, Div Hematol, Alessandria, Italy
[9] AOU San Giovanni Battista, Div Hematol 2, Turin, Italy
关键词
Telomere shortening; Cytogenetic abnormalities; Bone marrow failure; Tyrosine kinase inhibitors; Hematopoiesis; IMATINIB MESYLATE THERAPY; CLONAL CYTOGENETIC ABNORMALITIES; CHRONIC MYELOGENOUS LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; CHROMOSOMAL-ABNORMALITIES; POLYCLONAL HEMATOPOIESIS; CELLULAR SENESCENCE; CHRONIC-PHASE; DNA-DAMAGE; STEM-CELLS;
D O I
10.1016/j.mad.2012.05.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Telomere shortening, a well-known marker of aging and cellular stress, occurs under several conditions in the hematopoietic compartment, including aplastic anemia and following iatrogenic noxae. We decided to verify whether pathological telomere erosion also arises in restored Philadelphia-negative (Ph-negative) hematopoiesis following successful treatment of chronic myeloid leukemia (CML). Eighty-one CML patients in complete cytogenetic remission were compared to 76 age-matched healthy subjects. Myeloid cells of CML patients had shorter telomeres than controls (6521 bp vs 7233 bp, p < 0.001). This difference was specific for the myeloid compartment, since it was not observed in lymphoid cells (6774 bp vs 6909 bp, p = 0.620). Acquired Ph-negative cytogenetic abnormalities (p = 0.010), lack of complete molecular remission (p = 0.016) and age (p = 0.013) were independent predictors of telomere shortening. Telomere dynamics were assessed over a median follow-up period of 22 months. We. documented accelerated non-physiological ongoing telomere shortening in 17/59 CML patients (28%). Patients experiencing grade 2-4 hematological toxicity, during CML remission possessed significantly shorter telomeres compared to those lacking toxicity (p = 0.005 for any toxicity, p = 0.007 for anemia). CML patients suffer from significant and often ongoing telomere stress resulting in premature and selective aging of the myeloid compartment which might have long-term consequences on function and integrity of Ph-negative hematopoiesis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:479 / 488
页数:10
相关论文
共 50 条
  • [41] Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia
    Cannella, Laura
    Loglisci, Giuseppina
    Nanni, Mauro
    De Cuia, Maria Rosaria
    Colafigli, Gioia
    Salaroli, Adriano
    Serrao, Alessandra
    Alimena, Giuliana
    Breccia, Massimo
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 497 - 498
  • [42] The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells
    Deininger, Michael W. N.
    Cortes, Jorge
    Paquette, Ron
    Park, Byung
    Hochhaus, Andreas
    Baccarani, Michele
    Stone, Richard
    Fischer, Thomas
    Kantarjian, Hagop
    Niederwieser, Dietger
    Gambacorti-Passerini, Carlo
    So, Charlene
    Gathmann, Insa
    Goldman, John M.
    Smith, Douglas
    Druker, Brian J.
    Guilhot, Francois
    CANCER, 2007, 110 (07) : 1509 - 1519
  • [43] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
    Ciftciler, R.
    Haznedaroglu, I. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) : 7787 - 7798
  • [44] Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
    Kong, Jee Hyun
    Winton, Elliott F.
    Heffner, Leonard T.
    Gaddh, Manila
    Hill, Brittany
    Neely, Jessica
    Hatcher, Angela
    Joseph, Meena
    Arellano, Martha
    El-Rassi, Fuad
    Kim, Audrey
    Khoury, Jean Hanna
    Kota, Vamsi K.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [45] Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence
    Baccarani, M.
    LEUKEMIA, 2017, 31 (04) : 1015 - 1016
  • [46] Asciminib - ABL Kinase Inhibitor in the Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Chemistry and Pharmacology Perspectives
    Shah, Umang
    Patel, Prachi
    Patel, Alkesh
    Gajjar, Dhruvi
    Patel, Mehul
    Solanki, Nilay
    Patel, Swayamprakash
    Patel, Ashish
    Maheshwari, Rajesh
    MINI-REVIEWS IN ORGANIC CHEMISTRY, 2025, 22 (02) : 177 - 188
  • [47] Insertion of the 3′ ABL region into the long arm of chromosome 1 in a Philadelphia chromosome-negative chronic myeloid leukemia case
    Al-Achkar, Walid
    Liehr, Thomas
    Wafa, Abdulsamad
    ONCOLOGY LETTERS, 2010, 1 (06) : 951 - 954
  • [48] A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
    Nathan Cantoni
    Roberto Sommavilla
    Patrick Seitz
    Elisabeth Kulenkampff
    Stefan Kahn
    Jean-François Lambert
    Adrian Schmidt
    Reinhard Zenhaeusern
    Stefan Balabanov
    BMC Cancer, 22
  • [49] Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies
    Cheng, Fang
    Xu, Qiling
    Li, Qiang
    Cui, Zheng
    Li, Weiming
    Zeng, Fang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events
    Sant'Antonio, Emanuela
    Camerini, Chiara
    Rizzo, Vincenzo
    Musolino, Caterina
    Allegra, Alessandro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (09) : 573 - 579